ROCHESTER, N.Y., March 26, 2015 – Vaccinex Inc., a clinical-stage biotechnology company engaged in the discovery and development of therapeutic monoclonal antibodies to treat cancer and neurodegenerative diseases, today announced publication of a manuscript entitled “CXCL13 antibody for the treatment of autoimmune disorders” in BMC Immunuology.*
CXCL13 is produced by follicular dendritic cells and macrophage in secondary lymphoid organs and acts through its cognate receptor, CXCR5, on B cells and subsets of helper T cells. Overexpression of CXCL13 is linked to autoimmune diseases including rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosis. This new publication describes identification of a fully human anti-CXCL13 antibody and preclinical evaluation of the effect of blockade in mouse models of disease. It is demonstrated that blocking CXCL13 activity may be a powerful strategy to alleviate the detrimental effects of aberrant B and T-cell activity in inflammatory disease.
* Link to the article – http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4329654/
About Vaccinex, Inc.
Vaccinex, Inc. is a privately held clinical-stage immunotherapy company engaged in the discovery and development of human therapeutic monoclonal antibodies to treat cancer and neurodegenerative diseases, including multiple sclerosis and Huntington’s Disease. Vaccinex utilizes its proprietary ActivMAb® Antibody Discovery Technology for rapid, mammalian cell-based antibody selection to build its antibody pipeline and in service to its biopharmaceutical partners. Compared to other selection technologies, ActivMAb® combines the advantages of rapid and sensitive selection by virus panning and cell sorting in one technology, with intrinsic selection of antibodies that are efficiently expressed and stable in mammalian cells. Vaccinex is based in Rochester, New York. For more information and to contact Vaccinex, visit www.vaccinex.com.